US Edition
Kainova Reports Positive Top Line Results From Phase I EPRAD Trial
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Verdict Hospital
Clinical Trials ArenaKainova reports positive top line results from Phase I EPRAD trial
Kainova Therapeutics has reported positive top line results from the Phase I EPRAD study of DT-9081 in patients with advanced, recurrent, and metastatic solid tumours.The post Kainova reports positive top line results from Phase I EPRAD trial appeared first on Hospital Management.
Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors
Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance Montreal, Canada – Strasbourg, France – Boston, United States, March 10, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today […] The post Kainova Therap…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium